Immunotherapy
Immunotherapy works by harnessing the body’s own immune system and offers options for powerful, yet well-tolerated, therapies. Examples include monoclonal antibodies (rituximab, obinutuzumab, and others) that recognize the cancer, drugs that modulate the immune system, and others that take the brakes off of the immune system. These drugs are often combined with other types of therapy.
ARTICLES ON IMMUNOTHERAPY
Epcoritamab, a novel bispecific antibody monotherapy, showed strong results in relapsed / refractory high-risk CLL patients.
Epcoritamab, a bispecific antibody, shows encouraging early results in relapsed / refractory chronic lymphocytic leukemia (CLL) patients.
With the introduction of BTK inhibitors to treat CLL, there has been no disparity in survival outcomes for patients of different races and ethnicities.
This should not be part of anyone’s game plan. Still, it was nice to read that for at least this one 67-year-old asymptomatic CLL patient, a case of COVID-19 associated with low blood counts and a broad spectrum of treatments resulted in his CLL becoming undetectable in his bone
Immunotherapy for chronic lymphocytic leukemia/small lymphocytic lymphoma or CLL / SLL holds the promise of harnessing the body’s immune system to recognize and eliminate cancer.
This research was presented by Dr. Arnon Kater and colleagues at the American Society for Hematology annual meeting which was held December 2021 (ASH 2021).
RECENT NEWS
When appropriate, the CLL Society will be posting updates and background information on the present Coronavirus pandemic focusing on reliable primary sources of information and avoiding most of the news that is not directly from reliable medical experts or government and world health agencies.
